Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study
Clinical Gastroenterology and Hepatology · 2025-04 · 23 (5) · 766-775
DOI: 10.1016/j.cgh.2024.07.048 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-04. Verfasst von Megan M L Engels und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida; Division of Gastroenterology and Hepatology, Leiden University Medic…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, CA-19-9 Antigen, DNA Methylation, Pancreatic Juice. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Medtronic, National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND AND AIMS: In previous studies, methylated DNA markers (MDMs) have been identified in pancreatic juice (PJ) for detecting pancreatic ductal adenocarcinoma (PDAC). In this prospective multicenter study, the sensitivity and specificity characteristics of this panel of PJ-MDMs was evaluated standalone and in combination with plasma carbohydrate antigen 19-9 (CA 19-9). METHODS: Paired PJ and plasma were assayed from 88 biopsy-proven treatment-naïve PDAC cases and 134 controls (53 with normal pancreas, 23 with chronic pancreatitis [CP], 58 with intraductal papillary mucinous neoplasm). Bisulfite-converted DNA from buffered PJ was analyzed using long-probe quantitative amplified signal assay targeting 14 MDMs (NDRG4, BMP3, TBX15, C13orf18, PRKCB, CLEC11A, CD1D, ELMO1, IGF2BP1, RYR2, ADCY1, FER1L4, EMX1, and LRRC4) and a reference gene (methylated B3GALT6). Logistic regression was used to fit the previously identified 3-MDM PJ panel (FER1L4, C13orf18, and BMP3). Discrimination accuracy was summarized using area under the receiver-operating characteristic curve (AUROC) with corresponding 95% confidence interval (CI). RESULTS: Methylated FER1L4 had the highest individual AUROC of 0.83 (95% CI, 0.78-0.89). The AUROC for the 3-MDM PJ + plasma CA 19-9 model (0.95; 95% CI, 0.92-0.98) was higher than both the 3-MDM PJ panel (0.87; 95% CI, 0.82-0.92)) and plasma CA 19-9 alone (0.91; 95% CI, 0.87-0.96) (P = .0002 and .0135, respectively). At a specificity of 88% (95% CI, 81%-93%), the sensitivity of this model was 89% (95% CI, 80%-94%) for all PDAC stages and 83% (95% CI, 64%-94%) for stage I/II PDAC. CONCLUSIONS: A panel combining PJ-MDMs and plasma CA 19-9 discriminates PDAC from both healthy and disease control groups with high accuracy. This provides support for combining PJ and blood-based biomarkers for enhancing diagnostic sensitivity and successful early PDAC detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida; Division of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
- Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida.
- Division of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida; Division of Gastroenterology and Hepatology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates.
Förderung
- NCI NIH HHS
- Medtronic
- National Cancer Institute
- Mayo Clinic
- Boston Scientific Corporation
Zitieren
APA
Engels, M. M. L., Berger, C. K., Mahoney, D. W., Hoogenboom, S. A., Sarwal, D., Klatte, D. C. F., De La Fuente, J., Gandhi, S., Taylor, W. R., Foote, P. H., Doering, K. A., Delgado, A. M., Burger, K. N., Abu Dayyeh, B. K., Bofill-Garcia, A., Brahmbhatt, B., Chandrasekhara, V., Gleeson, F. C., Gomez, V., …, & Majumder, S. (2025). Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study. Clinical Gastroenterology and Hepatology, 23(5), 766-775. https://doi.org/10.1016/j.cgh.2024.07.048
Vancouver
Engels MML, Berger CK, Mahoney DW, Hoogenboom SA, Sarwal D, Klatte DCF, et al. Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study. Clinical Gastroenterology and Hepatology. 2025;23(5):766-775. doi:10.1016/j.cgh.2024.07.048
BibTeX
@article{Engels2025,
author = {Engels, Megan M L and Berger, Calise K and Mahoney, Douglas W and Hoogenboom, Sanne A and Sarwal, Dhruv and Klatte, Derk C F and De La Fuente, Jaime and Gandhi, Sonal and Taylor, William R and Foote, Patrick H and Doering, Karen A and Delgado, Adriana M and Burger, Kelli N and Abu Dayyeh, Barham K and Bofill-Garcia, Aliana and Brahmbhatt, Bhaumik and Chandrasekhara, Vinay and Gleeson, Ferga C and Gomez, Victoria and Kumbhari, Vivek and Law, Ryan J and Lukens, Frank J and Raimondo, Massimo and Rajan, Elizabeth and Storm, Andrew C and Vargas Valls, Eric J and van Hooft, Jeanin E and Wallace, Michael B and Kisiel, John B and Majumder, Shounak},
title = {Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
volume = {23},
number = {5},
pages = {766--775},
doi = {10.1016/j.cgh.2024.07.048}
}
EUVIMED